Risk Indicators in Patients With Ventricular Fibrillation During Acute Myocardial Infarction

Acute Myocardial Infarction Clinical Trial

Official title:

Indicators of Coagulation Activation and Inflammation Contributing to Ventricular Fibrillation Complicating Acute Myocardial Infarction

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00175942
• Other study ID #: 0229.3
• Status: Recruiting
• Phase: N/A
• First received: September 10, 2005
• Last updated: September 10, 2005
• Start date: February 2003

Study information

• Verified date: May 2005
• Source: Heidelberg University
• Contact: Elif Elmas, MD, Dr.
• Phone: 00496213833988
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Observational

Clinical Trial Summary

Sudden cardiac death is in most cases triggered by ischemia-related ventricular tachyarrhythmias and accounts for 50% of deaths from cardiovascular disease in developed countries. Chronic elevation of indicators of coagulation activation has been found in patients with coronary heart disease , but a role of coagulation activation and proinflammatory state as a potential risk factor for ventricular fibrillation (VF) during acute myocardial infarction has not been investigated.

Description:

Sudden cardiac death (SCD) is in most cases triggered by ischemia-related ventricular arrhythmias and is responsible for 50% of the mortality from cardiovascular disease in developed countries (1). Chronic elevation of indicators of coagulation activation and inflammation has been found in patients with coronary heart disease and may contribute to vasculatory disorders probably contributing to the development of arrhythmogenesis. However, the role of coagulation activation as a potential risk factor for ventricular fibrillation during acute myocardial infarction has not been investigated yet.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

ST-elevation myocardial infarction ventricular fibrillation during acute MI

Exclusion Criteria:

NSTEMI coagulation disorders, e.g.intake of coumadin

Study Design

Observational Model: Defined Population, Time Perspective: Longitudinal

Related Conditions & MeSH terms

• Acute Myocardial Infarction
• Death, Sudden, Cardiac
• Infarction
• Myocardial Infarction
• Sudden Cardiac Death
• Ventricular Fibrillation

Locations

Country	Name	City	State
Germany	University Hospital of Mannheim, University of Heidelberg	Mannheim

Sponsors (1)

Lead Sponsor	Collaborator
Heidelberg University

Country where clinical trial is conducted

Germany,